List of Excipients in Branded Drug QUVIVIQ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Idorsia Pharmaceuticals Ltd	QUVIVIQ	daridorexant	80491-7825	FERRIC OXIDE RED	2034-12-02
Idorsia Pharmaceuticals Ltd	QUVIVIQ	daridorexant	80491-7825	FERROSOFERRIC OXIDE	2034-12-02
Idorsia Pharmaceuticals Ltd	QUVIVIQ	daridorexant	80491-7825	GLYCERIN	2034-12-02
Idorsia Pharmaceuticals Ltd	QUVIVIQ	daridorexant	80491-7825	HYPROMELLOSE	2034-12-02
Idorsia Pharmaceuticals Ltd	QUVIVIQ	daridorexant	80491-7825	MAGNESIUM STEARATE	2034-12-02
Idorsia Pharmaceuticals Ltd	QUVIVIQ	daridorexant	80491-7825	MANNITOL	2034-12-02

QUVIVIQ Excipient Strategy and Commercial Opportunities for Daridorexant

Last updated: August 10, 2026

QUVIVIQ (daridorexant) uses a conventional immediate-release film-coated tablet platform with widely available excipients. The commercial opportunity is therefore concentrated in supply reliability, low-cost equivalent formulations, differentiated oral solid-dose products, and excipient technologies that improve manufacturability or enable lifecycle extensions. The current formulation creates limited barriers for generic manufacturers because it does not depend on a novel delivery system, complex release mechanism, or specialized excipient.

What is the QUVIVIQ formulation and which excipients does it contain?

QUVIVIQ is an immediate-release, film-coated tablet containing daridorexant, a dual orexin receptor antagonist approved for adults with insomnia characterized by difficulties with sleep onset or sleep maintenance. The FDA approved QUVIVIQ in January 2022 in 25 mg and 50 mg strengths.[1]

QUVIVIQ inactive ingredients

The U.S. prescribing information identifies the following core excipients:

Formulation component	Excipient
Tablet core	Lactose monohydrate
Tablet core	Microcrystalline cellulose
Tablet core	Crospovidone
Tablet core	Povidone
Tablet core	Colloidal silicon dioxide
Tablet core	Magnesium stearate
Film coating	Polyvinyl alcohol
Film coating	Titanium dioxide
Film coating	Talc
Film coating	Polyethylene glycol

The formulation is consistent with a standard direct-compression or high-shear granulation tablet platform. Lactose and microcrystalline cellulose provide bulk and compressibility. Crospovidone supports tablet disintegration. Povidone can function as a binder, while colloidal silicon dioxide improves powder flow. Magnesium stearate is the lubricant. The coating system provides color, opacity, surface protection, and swallowability.[1]

The label does not identify a controlled-release matrix, enteric coating, lipid vehicle, cyclodextrin complex, amorphous solid dispersion, or other specialized delivery technology.

What excipient technologies are most relevant to QUVIVIQ?

The highest-value excipient opportunities involve manufacturability and substitution rather than a new therapeutic delivery mechanism.

Direct-compression excipients

Microcrystalline cellulose and lactose are standard choices, but manufacturers can evaluate:

• Co-processed microcrystalline cellulose systems
• Spray-dried lactose
• Anhydrous lactose
• Dibasic calcium phosphate
• Mannitol-based fillers
• Silicified microcrystalline cellulose
• Low-moisture excipient grades

A co-processed filler-disintegrant could reduce segregation, improve flow, and support lower compression-force variability. The commercial value would be greatest if it reduced tablet weight, improved throughput, or lowered rejection rates without changing dissolution.

Disintegrants

Crospovidone is a conventional superdisintegrant. Alternatives include sodium starch glycolate and croscarmellose sodium. These substitutions may alter:

• Disintegration time
• Dissolution profile
• Tablet friability
• Sensitivity to compression force
• Stability under humidity
• Bioequivalence risk

A generic manufacturer should treat the disintegrant as a critical material attribute. A formulation that matches QUVIVIQ dissolution at one pH but diverges under multiple-pH testing could create regulatory or development delays.

Lubricants and flow aids

Magnesium stearate is widely used but can cause hydrophobicity and dissolution changes when over-lubrication occurs. Commercial opportunities exist for:

• Optimized magnesium stearate grades
• Sodium stearyl fumarate
• Reduced-lubrication manufacturing processes
• Surface-treated flow aids
• Continuous blending systems

These changes are more likely to support process improvement than patent differentiation. They may reduce sensitivity to blending time and improve scale-up performance.

Film-coating systems

The coating is a relatively accessible area for suppliers. Potential offerings include:

• Lower-solids aqueous coating systems
• Ready-to-use color coating premixes
• Titanium-dioxide-free white coatings
• Low-dusting coating systems
• Faster-drying polyvinyl alcohol coatings
• Coatings with improved moisture protection
• Vegan or allergen-positioned coating systems

A coating change may be commercially useful when it reduces production time, improves appearance consistency, or addresses regional excipient restrictions. It is unlikely by itself to create a strong proprietary barrier unless combined with a novel manufacturing process or a differentiated product claim.

What excipient strategy should a generic QUVIVIQ manufacturer use?

A generic manufacturer should prioritize a robust, low-risk formulation over aggressive excipient differentiation. Daridorexant is a small-molecule immediate-release tablet, making an ANDA pathway the likely regulatory route for a conventional equivalent product.

Recommended generic development strategy

Development objective	Preferred approach
Match reference performance	Use the same excipient classes where practical
Reduce cost	Evaluate regional lactose, MCC, crospovidone, and coating suppliers
Improve robustness	Use co-processed filler systems and design-of-experiment optimization
Control dissolution	Manage lubricant level, compression force, particle size, and disintegrant grade
Reduce supply risk	Qualify at least two suppliers for each critical excipient
Simplify global registration	Select excipients with broad pharmacopoeial coverage
Minimize clinical risk	Avoid major changes to tablet weight, coating, and disintegration behavior

The primary critical quality attributes are likely to include assay, content uniformity, impurities, hardness, friability, disintegration, dissolution, appearance, and stability. Because daridorexant exposure and pharmacokinetics can be affected by food, comparative fed and fasting performance will be important in development planning.[1]

A formulation that uses different excipients may still qualify as a generic equivalent, but the manufacturer must demonstrate pharmaceutical equivalence and bioequivalence under applicable FDA requirements. Excipient changes that materially modify dissolution or gastrointestinal behavior can increase development risk.

What excipient substitutions create the strongest commercial opportunities?

The best opportunities are products that lower total manufacturing cost while preserving the QUVIVIQ performance profile.

Lactose substitution

Lactose is inexpensive and widely available, but lactose-free or low-lactose platforms could appeal to certain markets and contract manufacturers. Candidate replacements include mannitol, dibasic calcium phosphate, and selected grades of microcrystalline cellulose.

The main trade-offs are tablet density, mouthfeel, compression behavior, and cost. A lactose-free product would not automatically create a new market category, but it could reduce dependence on lactose supply and support regional product positioning.

Co-processed excipient platforms

Co-processed excipients can combine filler, binder, and disintegrant functions. Their commercial value is highest when they:

• Reduce the number of raw materials
• Improve powder flow
• Reduce blend segregation
• Permit direct compression
• Shorten granulation or drying steps
• Improve tablet uniformity
• Reduce manufacturing footprint

For QUVIVIQ, a co-processed platform could be attractive to high-volume generic manufacturers and contract development and manufacturing organizations. The regulatory case would remain manageable if the final tablet matches reference dissolution and bioequivalence requirements.

Moisture-control excipients

Daridorexant tablets may benefit from low-moisture excipient grades and protective packaging if moisture affects impurities, hardness, or dissolution. Suppliers offering low-moisture lactose, MCC, silica, or film-coating systems could target manufacturers seeking longer shelf life or reduced packaging requirements.

This opportunity is more relevant in humid markets and global supply chains than in a tightly controlled domestic manufacturing environment.

Titanium-dioxide-free coating

Titanium dioxide restrictions and customer preferences create a potential coating opportunity. A titanium-dioxide-free coating could replace opacity and color functions with calcium carbonate, starch-based systems, or alternative pigments, subject to regulatory acceptance and product appearance requirements.

The commercial opportunity is strongest for international launches because excipient acceptance varies by jurisdiction. A single coating platform that meets FDA, European, and other major-market requirements can reduce regional manufacturing complexity.

What patent protections cover QUVIVIQ and its formulation?

QUVIVIQ is protected through a combination of active-ingredient, composition, formulation, manufacturing, and method-of-use rights. The relevant patent categories may include:

• Daridorexant compound claims
• Pharmaceutical composition claims
• Solid-state or crystalline-form claims
• Dosage-form claims
• Treatment claims for insomnia
• Claims involving dosing before bedtime
• Pharmacokinetic or food-effect limitations
• Manufacturing-process claims

The FDA Orange Book is the controlling public source for patents listed against the approved QUVIVIQ product.[2] Patent scope and expiry must be assessed by jurisdiction because U.S. Orange Book listings do not determine European, Canadian, Japanese, or other national rights.

How strong is the QUVIVIQ patent estate?

The formulation itself appears commercially conventional, which limits the defensive value of ordinary excipient claims. A patent directed only to lactose, MCC, crospovidone, povidone, silica, and magnesium stearate would likely face substantial prior-art exposure.

The stronger protection is more likely to come from:

1. The daridorexant molecule and related chemical genus.
2. Specific crystalline or solid-state forms.
3. Therapeutic use in insomnia.
4. Dose and administration claims.
5. Product-specific pharmacokinetic or food-effect claims.
6. Manufacturing methods that produce a defined solid form or impurity profile.

An excipient supplier should not assume that a generic QUVIVIQ formulation is free of patent risk merely because it uses common inactive ingredients. Risk depends on the claims in force, the proposed formulation, the dosage regimen, and the jurisdiction.

When does QUVIVIQ lose exclusivity?

QUVIVIQ’s regulatory exclusivity and patent exclusivity are separate.

Protection type	Strategic relevance
New chemical entity exclusivity	Prevents FDA approval of an ANDA or 505(b)(2) application for the exclusivity period
Orange Book patents	May delay or complicate generic approval and launch
Method-of-use patents	Can require skinny-label strategies or carve-outs
Formulation patents	May affect specific dosage forms or release profiles
Regulatory exclusivity outside the U.S.	Varies by jurisdiction and product classification

The FDA approved QUVIVIQ as a new chemical entity in 2022. The standard U.S. NCE exclusivity period generally runs for five years, subject to the timing of generic filings and statutory exceptions.[3] That period does not establish the final commercial launch date for an ANDA product because listed patents and patent litigation may extend the effective barrier.

Patent expiry dates should be confirmed against the current Orange Book and individual patent records. A generic applicant must evaluate both the earliest non-infringing launch opportunity and the risk that a Paragraph IV certification triggers litigation.

What Paragraph IV challenges and generic entry risks exist for QUVIVIQ?

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. For QUVIVIQ, a generic applicant could face several possible strategies:

• Challenge compound or composition patents.
• Accept patents that remain valid and challenge only later-expiring rights.
• File a skinny label excluding patented methods of use.
• Pursue a settlement with the patent holder.
• Launch at risk after litigation milestones.
• Wait for patent expiry and avoid Paragraph IV litigation.

The principal generic entry risks are:

1. Compound-patent risk. A valid compound patent can block conventional daridorexant tablets regardless of excipient selection.
2. Solid-state risk. A patent covering a particular crystalline form may affect the active pharmaceutical ingredient used in a generic product.
3. Method-of-use risk. A label carve-out may be difficult if the patented indication overlaps substantially with the approved insomnia indication.
4. Regulatory timing risk. FDA approval timing can be affected by NCE exclusivity, patent litigation, and certification requirements.
5. Commercial substitution risk. Even after approval, payer controls and physician familiarity may affect uptake.

Excipient innovation is therefore more valuable as a cost and supply-chain strategy than as a standalone route around core active-ingredient patents.

Does QUVIVIQ create biosimilar or generic excipient opportunities?

QUVIVIQ does not create a biosimilar opportunity because daridorexant is a chemically synthesized small molecule. The relevant competitive pathway is an ANDA-based generic, not a 351(k) biosimilar application.

The excipient market opportunity is indirect. Suppliers can sell:

• Reference-equivalent excipients
• Co-processed tablet platforms
• Film-coating systems
• Low-moisture grades
• Alternative-color coating systems
• Development and scale-up services
• Bioequivalence-support formulations

A supplier with a ready-to-use platform that reproduces QUVIVIQ dissolution and tablet mechanics can reduce development time for multiple generic manufacturers.

What licensing and commercial partnership opportunities exist?

The most practical licensing structures involve formulation technology, not the daridorexant molecule.

Potential deal structures

Opportunity	Likely counterparties	Commercial rationale
Co-processed excipient license	Generic companies, CDMOs	Faster direct-compression development
Film-coating technology	Tablet manufacturers, coating suppliers	Lower cycle time and regional compliance
Formulation package	ANDA applicants	Reduced development and scale-up work
Supply agreement	Excipient producers, contract manufacturers	Volume security and dual sourcing
Manufacturing-process license	Generic manufacturers	Improved blend uniformity or dissolution control
Geographic formulation rights	Regional drug companies	Localized excipient and regulatory adaptation

A formulation technology license should include freedom-to-operate analysis, change-control rights, supplier qualification, analytical method transfer, and responsibility for regulatory filings. Royalty value will depend on whether the technology provides a measurable advantage over standard excipient substitution.

What manufacturing and intellectual-property barriers affect QUVIVIQ competitors?

The manufacturing barrier is moderate. QUVIVIQ uses established tablet technologies, and the listed excipients are generally available from multiple global suppliers. The main barriers are likely to be:

• Access to suitable daridorexant API
• Control of particle size and solid form
• Impurity management
• Dissolution matching
• Scale-up reproducibility
• Bioequivalence
• Patent clearance
• Global excipient compliance
• Reliable commercial supply

A generic manufacturer that relies on a single API source or a single specialty excipient supplier faces avoidable launch risk. Dual sourcing is particularly important for lactose, MCC, crospovidone, coating polymers, pigments, and pharmaceutical-grade silica.

How does QUVIVIQ compare with competing insomnia medicines?

QUVIVIQ competes with other dual orexin receptor antagonists, including BELSOMRA (suvorexant) and DAYVIGO (lemborexant), as well as non-orexin insomnia therapies such as zolpidem, eszopiclone, and temazepam.

Product	Active ingredient	Dosage-form complexity	Excipient opportunity
QUVIVIQ	Daridorexant	Conventional immediate-release tablet	High for generic cost reduction and supply optimization
BELSOMRA	Suvorexant	Conventional tablet	Similar generic-tablet opportunity, subject to patent status
DAYVIGO	Lemborexant	Conventional tablet	Similar formulation and coating opportunities
Zolpidem products	Zolpidem	Tablets, sublingual, extended-release forms	Broader delivery-system competition
Eszopiclone	Eszopiclone	Immediate-release tablet	Mature generic market with strong price pressure

QUVIVIQ’s commercial differentiation is primarily pharmacologic and clinical rather than excipient-based. An excipient strategy should support reliable performance and low cost rather than attempt to create a new delivery category without a clear clinical benefit.

What is the regulatory status of QUVIVIQ and its formulation?

FDA approved QUVIVIQ tablets under a new drug application for adult insomnia.[1] The product is not an extended-release dosage form and does not require a complex device, injectable presentation, or biologic comparability program.

For a conventional generic, the main regulatory workstreams are:

• Pharmaceutical equivalence
• Comparative dissolution
• Bioequivalence
• Stability
• Impurity characterization
• Manufacturing-process validation
• Label and patent certification
• Facility compliance

Excipient changes should be assessed under FDA guidance on inactive ingredients, pharmaceutical equivalence, and ANDA product development. A formulation using excipients outside established levels or with novel functionality may require additional justification.

What revenue exposure and market opportunities exist for excipient suppliers?

The addressable opportunity is linked to the future generic market and to manufacturing efficiency for branded and generic tablets. The product has two strengths, a conventional tablet format, and no device-dependent delivery system. These factors favor multiple-source excipient procurement and contract manufacturing.

The most attractive commercial segments are:

1. High-volume generic tablet manufacturers.
2. CDMOs developing small-molecule insomnia products.
3. Coating suppliers serving global markets.
4. Excipient companies with direct-compression platforms.
5. API and formulation suppliers offering an integrated daridorexant development package.

The commercial value of a QUVIVIQ excipient platform will be measured by lower cost per tablet, reduced development time, improved dissolution matching, fewer manufacturing deviations, and regulatory portability across markets.

Key Takeaways

• QUVIVIQ is a conventional immediate-release, film-coated daridorexant tablet.
• Its core excipients include lactose monohydrate, microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, and magnesium stearate.
• The strongest excipient opportunities involve direct compression, coating efficiency, moisture control, and supply-chain resilience.
• QUVIVIQ does not create a biosimilar opportunity; competitive entry will use small-molecule generic pathways.
• Core patent risk is more likely to involve daridorexant, solid forms, dosing, and methods of use than ordinary excipient selection.
• The FDA Orange Book should be used to verify current listed patents and expiry information.
• A co-processed excipient or ready-to-use coating platform could have licensing value for generic manufacturers and CDMOs.
• Conventional formulation technology means the technical manufacturing barrier is moderate, but API, solid-form, bioequivalence, and patent barriers remain material.

FAQs

Can QUVIVIQ be reformulated without lactose?

Yes. A lactose-free daridorexant tablet could use mannitol, dibasic calcium phosphate, or alternative cellulose-based fillers, provided the product meets pharmaceutical equivalence, dissolution, stability, and bioequivalence requirements.

Which excipient is most important for matching QUVIVIQ dissolution?

The disintegrant and lubricant system are likely to be especially important. Crospovidone grade, magnesium stearate concentration, blending time, compression force, and tablet porosity can materially affect disintegration and dissolution.

Is a QUVIVIQ co-processed excipient formulation patentable?

Potentially, but ordinary substitution of common excipients is unlikely to provide strong patent protection. A stronger case would require a defined composition, measurable performance advantage, or manufacturing process that is novel and non-obvious.

Can a generic QUVIVIQ manufacturer use a different film coating?

Yes. A different film coating may be permissible if the finished product meets applicable quality, appearance, stability, dissolution, and bioequivalence requirements. Regional excipient restrictions should be assessed before selecting a global coating system.

Is QUVIVIQ more exposed to generic competition than injectable insomnia drugs?

Yes. Its conventional oral tablet format generally presents fewer manufacturing barriers than an injectable or device-dependent product. Generic timing will still depend on NCE exclusivity, Orange Book patents, Paragraph IV litigation, settlements, and FDA approval.

References

1. U.S. Food and Drug Administration. (2022). QUVIVIQ (daridorexant) prescribing information. Idorsia Pharmaceuticals U.S. Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Small business assistance: Frequently asked questions on the patent term restoration and the FDA. https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patent-term-restoration-and-fda

4. U.S. Food and Drug Administration. (2017). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (2014). Guidance for industry: ANDAs for certain highly soluble, highly permeable, orally administered drug products. U.S. Department of Health and Human Services.